Complete androgen blockade for prostate cancer: What went wrong?

Journal of Urology

Volumn 164, Issue 1, 2000, Pages 3-9

  Laufer, Menachem ^a   Denmeade, Samuel R ^a   Sinibaldi, Victoria J ^a   Carducci, Michael A ^a   Eisenberger, Mario A ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Androgen antagonists; Castration; Male; Neoplasm metastasis; Prostate; Prostatic neoplasms

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; BUSERELIN; CYPROTERONE ACETATE; FLUTAMIDE; GOSERELIN; LEUPRORELIN; NILUTAMIDE;

ANEMIA; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FATIGUE; HUMAN; IMPOTENCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MASTALGIA; META ANALYSIS; ORCHIECTOMY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0033934609     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67436-8     Document Type: Review

References (72)

1. Denmeade. S. R., Lin, X. S, and Isaacs, J. T.: Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate, 28: 251, 1996
2. Huggins, C. and Hodges, C. V.: Studies on prostate cancer: effect of castration, of estrogen and of androgen injection on serum acid phosphatase in metastatic carcinoma of the prostate. Cancer Res, 1: 293, 1941
3. Factors in the prognosis of carcinoma of the prostate: a cooperative study. Veterans Administration Cooperative Urological Research Group. J Urol. 100: 59, 1968
4. Byar, D. P.: Proceedings: the Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer, 32: 1126, 1973
5. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group Lancet, 346: 265, 1995
6. Leuprolide versus diethylstilbestrol for metastatic prostatic cancer. Leuprolide Study Group. N Engl J Med. 311: 1281, 1984
7. Parmar, H., Phillips, R. H., Lightman, S. H. et al: Randomised controlled study of orchidectomy vs. long-acting D-Trp-LHRH microcapsules in advanced prostatic carcinoma. Lancet, 2: 1201, 1985
8. Eisenberger, M. A., O'Dwyer, P. J. and Friedman, M. A.: Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma. J Clin Oncol. 4: 414, 1986
9. Turkes, A. O., Peeling, W. B. and Griffiths, K.: Treatment of patients with advanced cancer of the prostate: phase III trial, zoladex against castration; a study of the British Prostate Group. J Steroid Biochem. 27: 543, 1987
10. Byar, D. P. and Corle, D. K.: Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr, 7: 163, 1988
11. Peeling, W. B.: Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology, suppl., 33: 45, 1989
12. Soloway, M. S., Chodak, G., Vogelzang, N. J. et al: Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial, Urology, 37: 46, 1991
13. McLeod, D. G. and Kolvenbag, G. J.: Defining the role of anti-androgens in the treatment of prostate cancer. Urology, suppl., 47: 85, 1996
14. Iversen, P., Tveter, K. and Varenhorst, E.: Randomised study of Casodex 50 MG monotherapy vs. orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Casodex Cooperative Group. Scand J Urol Nephrol. 30: 93, 1996
15. Tyrell, C. J., Kaisary, A. V., Iversen, P. et al: A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol, 33: 447, 1998
16. Berges, R. R., Vukanovic, J., Epstein, J. I. et al: Implications of cell kinetic changes during the progression of human prostate cancer. Clin Cancer Res, 1: 473, 1995
17. Scher, H. I., Cardon-Cardo, C., Koff, A. et al: Alterations of cell cycle regulators in prostate cancer: response to androgen withdrawal and development of androgen independence. Proc Am Soc Clin Oncol, 18: 313a 1999
18. Isaacs, J. T., Cussenot, O., Jankevicius, F. et al: Growth regulation of normal and malignant prostatic cells. Presented at First International Consultation on Prostate Cancer, Monaco. June 20-22, 1996
19. Labrie, F., Dupont, A., Belanger, A. et al: Combination therapy with flutamide and castration (LHRH agonists or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem. 23: 833, 1985
20. Labrie, F., Veilleux, R. and Fournier, A.: Low androgen levels induce the development of androgen-hypersensitive cell clones in Shionogi mouse mammary carcinoma cells in culture. J Natl Cancer Inst, 80: 1138, 1988
21. Blumenstein, B. A.: Some statistical considerations for the interpretation of trials of combined androgen therapy. Cancer, suppl., 72: 3834, 1993
22. Crawlbrd, E. D., Eisenberger, M. A., McLeod, D. G. et al: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 321: 419, 1989
23. Bono, A. V., DiSilverio, F., Robustelli della Cuna, G. et al: Complete androgen blockade versus chemical castration in advanced prostatic cancer: analysis of an Italian multicentre study. Urol Int, suppl., 60: 18, 1998
24. Crawford, E. D., Kasimis, B. S., Gandara, D. et al: Arandomized, controlled clinical trial of leuprolide and anandron vs. leuprolide and placebo for advanced prostate cancer. Proc Am Soc Clin Oncol, 9: A523, 1990
25. Tyrell, C. J., Altwein, J. E., Klippel, F. et al: A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. J Urol, 146: 1321, 1991
26. Fourcade, R. O., Colombel, P. and Mangin, M.: Zoladex plus flutamide versus zoladex plus placebo in advanced prostatic carcinoma. Extended follow-up of the French multicenter study. In: Proceedings of the 3rd International Symposium on Recent Advances in Urology Cancer SCI. Edited by G. P. Murphy, p. 102, 1992
27. Boccardo, F., Pace, M., Rubagotti, A. et al: Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostatic cancer. Eur J Cancer, 29A: 1088, 1993
28. de Voogt, H. J., Studer, U., Schroder, F. H. et al: Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. Eur Urol. 33: 152, 1998
29. DiSilviero, F., Serio, M., D'Eramo, G. et al: Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study. Eur Urol, suppl., 18: 54, 1990
30. Thorpe, S. C., Azmatullah, S., Fellows, G. J. et al: A prospective randomized study to compare goserelin acetate (Zoladex) versus cyproterone acetate (CyproStat) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol, 29: 47, 1996
31. Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D. et al: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer, N Engl J Med, 339: 1036, 1998
32. Zalcberg, J. R., Raghaven, D., Marshall, V. et al: Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate: an Australian multicentre trial. Br J Urol. 77: 865, 1996
33. Dijkman, G. A., Janknegt, R. A., De Reijke, T. M. et al: Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer and the significance of early prostate specific antigen normalization. J Urol. 158: 160, 1997
34. Beland, G., Elhilali, M., Fradet, Y. et al: Total androgen ablation: Canadian experience. Urol Clin North Am, 18: 75, 1991
35. Jorgensen, T., Tveter, K. J. and Jorgensen, L. H.: Total androgen suppression: experience from the Scandinavian Prostatic Cancer Group Study No. 2. Eur Urol. 24: 466, 1993
36. Robinson, M. R. G., Smith, P. H., Richards, B. et al: The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol, 28: 273, 1995
37. Denis, L. J., Keuppens, F., Smith, P. H. et al: Maximal androgen blockade: final analysis of EORTC phase III trial 30853. Eur Urol, 33: 144, 1998
38. Iversen, P., Ramussen, F., Klarskov, P. et al: Long-term results of Danish Prostatic Cancer Group trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer. Cancer, suppl., 72: 3851, 1993
39. Kuhn, J,-M., Billebaud, T., Navratil, H. et al: Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med. 321: 413, 1989
40. Suciu, S., Sylvester, R., Iversen, P. et al: Comparability of prostate trials. Cancer, suppl.. 72: 3841, 1993
41. Schellhammer, P. F., Sharifi, R., Block, N. L. et al: Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Urology, 50: 330, 1997
42. Eisenberger, M. A., Crawford, E. D., Wolf, M. et al: Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). Semin Oncol, 21: 613, 1994
43. Ishikawa, S., Soloway, M. S., Van der Zwaag, R. et al: Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol, 141: 1139, 1989
44. Ernst, D. S., Hanson, J., Venner, P. M. et al: Analysis of prognostic factors in men with metastatic prostate cancer. J Urol, 146: 372, 1991
45. Waaler, G. and Nilssen, M. O.: Prognostic factors in disseminated prostatic cancer, with special emphasis on extent of disease. Urol Int, 53: 130, 1994
46. Sylvester, R., Denis, L. J. and de Voogt. H.: The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. Eur Urol, 33: 134, 1998
47. Matzkin, H., Eber, P., Todd. B. et al: Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. Cancer, 70: 2302, 1992
48. Pelger, R. C. M., Lycklama, A. Nijeholt, G. A. B. et al: The flare in serum alkaline phosphatase activity after orchiectomy: a valuable negative prognostic index for progression-free survival in prostatic carcinoma. J Urol. 156: 122, 1996
49. Thalmann, G. N., Sikes, R. A., Chang, S. M. et al: Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Inst, 88: 794, 1996
50. Prentice, R. L.: Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med, 8: 431, 1989
51. Eisenberger, M. A. and Nelson, W. G.: How much we can rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution! J Natl Cancer Inst, 88: 779, 1996
52. Caubet, J. F., Tosteson, T. D., Dong, E. W. et al: Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using non-steroidal antiandrogens. Urology. 49: 71, 1997
53. Bertagna, C., De Gery, A., Hucher, M. et al: Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomised double-blind trials (1056 patients). Br J Urol. 73: 396, 1994
54. Bennett, C. L., Tosteson, T. D., Schmitt, B. et al: Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer Prostatic Dis. 2: 4, 1999
55. Agency for Health Care Policy and Research Report No. 99-E012. http://www.ahcpr.gov/clinic/index.html#evidence. Accessed August 1999
56. Dijkman, G. A., Fernandez del Moral, P., Debruyne, F. M. et al: Improved subjective responses to orchiectomy plus nilutamide (anandron) in comparison to orchiectomy plus placebo in metastatic prostate cancer. Eur Urol, 27: 196, 1995
57. Altwein, J., Ekman, P., Barry, M. et al: How is quality of life in prostate cancer patients influenced by modern treatment? The Wallenberg Symposium. Urology, suppl., 49: 66, 1997
58. Moinpour, C. M., Savage, M. J., Troxel, A. et al: Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst, 90: 1537, 1998
59. Labrie, F., Belanger, A., Cusan, L. et al: History of LHRH agonist and combination therapy in prostate cancer. Endocrine-Related Cancer, 3: 243, 1996
60. Yan, G., Fukabori, Y., McBride, G. et al: Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGR receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol, 13: 4513, 1993
61. Liu, X. H., Wiley, H. S. and Meikle, A. W.: Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-alpha (TGF-alpha) and epidermal growth factor (EGF)/TGF-alpha receptor. J Clin Endocrinol Metab, 77: 1472, 1993
62. Cunha, G. R., Alarid, E. T., Turner, T. et al: Normal and abnormal development of the male urogenital tract. Role of androgens, mesenchymal-epithelial interactions, and growth factors. J Androl, 13: 465, 1992
63. Ocsterling, J. E., Epstein, J. I. and Walsh, P. C.: The inability of adrenal androgens to stimulate the adult human prostate: an autopsy evaluation of men with hypogonadotropic hypogonadism and panhypopituitarism. J Urol, 136: 1030, 1986
64. Folkman. J.: The role of angiogenesis in tumor growth. Semin Cancer Biol, 3: 65, 1992
65. Weidner, N., Carroll, P. R., Flax, J. et al: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol, 143: 401, 1993
66. Jackson, M. W., Bentel, J. M. and Tilley, W. D.: Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol, 157: 2323, 1997
67. Chambers, A. F. and Matrisian, L. M.: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 89: 1260, 1997
68. Taplin, M. E., Bubley, G. J., Shuster, T. D. et al: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 332: 1393, 1995
69. Culig, Z., Hobisch, A., Hittmair, A. et al: Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate, 35: 63, 1998
70. Wilding, G., Chen, M. and Gelmann, E. P.: Aberrant responses in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate, 14: 103, 1989
71. Tilley, W. D., Bentel, J. M., Aspinall, J. O. et al: Evidence for a novel mechanism of androgen resistance in the human prostate cancer cell line. PC-3. Steroids. 60: 180, 1995
72. Scher, H. I. and Kelly, W. K.: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol. 11: 1566, 1993